Kristina Sigmon

Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease

R. Califf, E. Topol, F. Van de Werf, 2003, Circulation.

Harmony Outcomes: A randomized, double‐blind, placebo‐controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics

Lawrence A Leiter, J. McMurray, C. Granger, 2018, American heart journal.

Inhibition of Platelet Aggregation with a Glycoprotein IIb-IIIa Antagonist Does Not Prevent Thrombin Generation in Patients Undergoing Thrombolysis for Acute Myocardial Infarction

R. Califf, E. Topol, E. Ohman, 2004, Journal of Thrombosis and Thrombolysis.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Diane M. Miller, Natalia E. Shilkina, M. C. Cantero, 2018, Lancet.